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Although insulin-like growth factor 2 (IGF2) has been reported to be overexpressed in
steatosis and steatohepatitis, a causal role of IGF2 in steatosis development remains
elusive. Aim of our study was to decipher the role of IGF2 in steatosis development.
Hydrodynamic gene delivery of an Igf2 plasmid used for transient Igf2 overexpression
employing codon-optimized plasmid DNA resulted in a strong induction of hepatic
Igf2 expression. The exogenously delivered Igf2 had no influence on endogenous Igf2
expression. The downstream kinase AKT was activated in Igf2 animals. Decreased
ALT levels mirrored the cytoprotective effect of IGF2. Serum cholesterol was increased
and sulfo-phospho-vanillin colorimetric assay confirmed lipid accumulation in Igf2-livers
while no signs of inflammation were observed. Interestingly, hepatic cholesterol and
phospholipids, determined by thin layer chromatography, and free cholesterol by filipin
staining, were specifically increased. Lipid droplet (LD) size was not changed, but their
number was significantly elevated. Furthermore, free cholesterol, which can be stored
in LDs and has been reported to be critical for steatosis progression, was elevated
in Igf2 overexpressing mice. Accordingly, Hmgcr/HmgCoAR was upregulated. To have
a closer look at de novo lipid synthesis we investigated expression of the lipogenic
transcription factor SREBF1 and its target genes. SREBF1 was induced and also
SREBF1 target genes were slightly upregulated. Interestingly, the expression of Cpt1a,
which is responsible for mitochondrial fatty acid oxidation, was induced. Hepatic IGF2
expression induces a fatty liver, characterized by increased cholesterol and phospholipids
leading to accumulation of LDs. We therefore suggest a causal role for IGF2 in hepatic
lipid accumulation.
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INTRODUCTION
Lipid accumulation is amajor feature accompanying all etiologies
of chronic hepatitis. Hepatitis is provoked by viral factors,
alcoholic, or non-alcoholic steatohepatitis. Chronic hepatitis
represents a risk factor for the development of hepatocellular
carcinoma (HCC), which is the second leading cause of cancer
related death in men (Jemal et al., 2011).
The hepatitis C virus (HCV) core protein was shown to
upregulate insulin-like growth factor 2 (IGF2) expression (Liu
et al., 2005; Nguyen et al., 2006). IGF2 has been reported to be
overexpressed in advanced stages of liver disease, i.e., cirrhosis
and HCC (Iizuka et al., 2002; Sedlaczek et al., 2003; Couvert
et al., 2008; Kessler et al., 2013). Igf2 transgenic mice carrying
a mostly urinary promoter show a higher frequency of diverse
malignancies (Rogler et al., 1994). Interestingly, genetic variants
of the IGF2 gene were correlated to obesity, obesity-associated
hypertension, and intramuscular fat (Faienza et al., 2010; Aslan
et al., 2012; Deodati et al., 2013). Although IGF2 has been
reported to be overexpressed in steatosis and steatohepatitis
(Chiappini et al., 2006; Tybl et al., 2011; De Minicis et al., 2014),
a causal role of IGF2 in steatosis development remains elusive.
IGF2 signaling can be involved in the transition of steatosis
and steatohepatitis to HCC due to downregulation of the tumor
suppressor PTEN by IGF2 (Horie et al., 2004; Vinciguerra et al.,
2008). On the other hand, IGF1 levels have been described
to be downregulated in steatotic patients (Völzke et al., 2009;
Mallea-Gil et al., 2012; Cianfarani et al., 2014).
Igf2 transgenic mice show fetal overgrowth and neonatal
lethality (Sun et al., 1997) and can therefore not be used to study
the role of IGF2 in steatosis. Hydrodynamic delivery displays a
simple and effective method for in vivo gene delivery (Liu et al.,
1999; Suda et al., 2006). It was demonstrated in mice that DNA,
RNA, and proteins but also small molecules can be delivered
to hepatocytes through tail vein injection (Herweijer and Wolff,
2006; Suda and Liu, 2007). Over 99% of gene expression following
a hydrodynamic tail vein delivery of plasmid DNA occurs in the
liver (Zhou et al., 2010). Thismight be due to the unique structure
of the liver sinusoids (Suda et al., 2006).
In this study we present that transient IGF2 overexpression
leads to hepatic lipid accumulation.
MATERIALS AND METHODS
Animals and Hydrodynamic Gene Delivery
Twenty-one six-week-old male C57BL/6JRj mice were purchased
from Janvier Labs (Saint-Berthevin Cedex, France) and were
directly delivered to their final destination. The mice were
adapted to the new environment for 1 week and housed with
4–6 mice/cage in a specific pathogen-free animal facility with
free access to food and water and with a 14-h light/10-h dark
cycle before proceeding with the hydrodynamic injection. Seven-
week-old C57BL/6JRj mice were rapidly injected (5 s) via the
tail vein with a volume corresponding to 10% of their body
weight containing plasmid DNA at a concentration of 12.5µg/ml
in sterile, endotoxin free PBS. This injection method leads to
transient hepatic expression of the plasmids (Pinheiro et al.,
2013). After 7 days the animals were sacrificed, liver weights
were estimated, and samples were collected. The experiment
was conducted in accordance with the regulations for animal
experiments at the University of Ghent.
Plasmids
The backbone of a pCpG-hCMV-EF1α-LucSH (luc luciferase,
sh neomycin resistance) plasmid, which has been shown to
induce high and stable expression levels of the luciferase
insert (Magnusson et al., 2011), was used for the generation
of the pCpG-hCMV-EF1α-Igf2 plasmid (Igf2). The protein
coding murine Igf2 cDNA sequence was chosen according
to published sequence data (NM_010514.3, NM_001122736.1,
NM_001122737.1), optimized for codon usage, flanked by BglII
and NheI restriction sites, synthesized by Eurofins Genomics
(Ebersberg, Germany), and finally cloned into the pCpG-hCMV-
EF1α backbone. The optimized insert sequence corresponds
to the published murine IGF2 protein amino acid sequence
data (NP_001116209.1, NP_001116208.1). All procedures were
performed according to published methods (Magnusson et al.,
2011; Su et al., 2013). Plasmid purification was done with
the EndoFree Plasmid Giga Kit from Qiagen (12391, Hilden,
Germany) under sterile, endotoxin free conditions. The final
plasmid sequence was validated by sequencing (Eurofins
Genomics). Ten mice were injected with the Luc plasmid as
control animals (co) and 11 mice were injected with the Igf2
plasmid (Igf2). The insert sequence is provided in Figure 1.
Plasmids were deposited at Addgene (http://www.addgene.org;
plasmid 67933, plasmid 67934).
Serum Parameters
Two days after injection blood glucose was determined by
a BGStar glucometer (MDSS GmbH, Hannover, Germany).
After 7 days animals were sacrificed and serum was collected.
Serum levels of high density lipoprotein (HDL), triglycerides,
cholesterol, aspartate aminotransferase (AST), and alanine
aminotransferase (ALT) were measured at the “Zentrallabor des
Universitätsklinikums des Saarlandes” (University of Saarland,
Homburg, Germany).
Real-Time RT-PCR
Real-time RT-PCR was performed as recently reported (Laggai
et al., 2014). Real-time RT-PCR was performed in a CFX96
cycler (Bio-Rad, Munich, Germany) with 5× HOT FIREPol R©
EvaGreen R© qPCR Mix Plus (Solis BioDyne, Tartu, Estonia). All
samples were measured in triplicate. Efficiency was determined
for each experiment using a cDNA dilution series with a standard
dilution series as described previously (Kiemer et al., 2009). The
relative gene expression was normalized to 18S mRNA values.
Details on primer sequences and conditions can be found in
Table 1.
Protein Isolation and Analysis by Western
Blot
Western blot of total tissue lysates was carried out as described
previously (Kessler et al., 2013; Laggai et al., 2014). Anti-α-
tubulin (T9026, Sigma Aldrich, Taufkirchen, Germany, 1:1000
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FIGURE 1 | Plasmid sequence and vector maps. The sequence of the Igf2 insert is shown. Restriction sites are highlighted in gray.
TABLE 1 | Primer sequences and conditions.
Gene Forward primer sequence 5′–3′ Reverse primer sequence 5′–3′ Amplicon
size [bp]
Gene bank
accession
number
Primer
[nM]
Annealing Temp.
[◦C]
18s AGGTCTGTGATGCCCTTAGA GAATGGGGTTCAACGGGTTA 109 NR_003278.3 250 61
Acaca TGGAGCTAAACCAGCACTCC GTGTATCTGAGCTGACGGAGG 141 NM_133360.2 200 60
Cpt1a CTCAGTGGGAGCGACTCTTCA GGCCTCTGTGGTACACGACAA 105 NM_013495.2 250 60
Elovl6 ACAATGGACCTGTCAGCAAA GTACCAGTGCAGGAAGATCAGT 119 NM_130450.2 100 60
Emr1 CTTTGGCTATGGGCTTCCAGTC GCAAGGAGGACAGAGTTTATCGTG 165 NM_010130 150 60
exogenous Igf2 CACGAGCAAACAGACGTTCC CTCACGTCCCGTTCACTCTT 100 − 200 60
Fasn ATCCTGGAACGAGAACACGATCT AGAGACGTGTCACTCCTGGACTT 140 NM_007988.3 150 60
Gck GGACTCCACACCCCACAAAT GCTGTCTCACTGGCTGACTT 113 NM_010292.4 250 60
Hmgcr ATCCAGGAGCGAACCAAGAGAG CAGAAGCCCCAAGCACAAAC 99 NM_008255.2 250 60
IGF2 GGAAGTCGATGTTGGTGCTTCTC CGAACAGACAAACTGAAGCGTGT 121 NM_010514.3 250 60
Mlxipl CTGGGGACCTAAACAGGAGC GAAGCCACCCTATAGCTCCC 166 NM_021455.4 250 60
Nr1h3 CCGACAGAGCTTCGTCC CCCACAGACACTGCACAG 81 NM_013839.4 200 60
Pklr GCTCTGGCCCTGGATCTTTA CTGGCACGTCTCAGGTATCC 96 NM_013631.2 200 60
Ppara CCTTCCCTGTGAACTGACG CCACAGAGCGCTAAGCTGT 77 NM_001113418.1 250 60
Scd AGATCTCCAGTTCTTACACGACCAC CTTTCATTTCAGGACGGATGTCT 140 NM_009127.4 200 60
Srebf1c GGCTCTGGAACAGACACTGG GGCCCGGGAAGTCACTGT 110 NM_011480.3 100 60
in PBST + 5% dry milk) and anti-SREBF1 [ab3259, Abcam,
Cambridge, UK, 1:200 in Rockland blocking buffer (RBB; MB-
070, Gilbertsville, USA)] antibodies were incubated for 3 h at
room temperature. Anti-pAKT antibody (#4060P, Cell Signaling
Technology, Danvers, USA, 1:1000 in RBB) was incubated
overnight at 4◦C. Secondary antibodies against mouse IgG
[for tubulin and SREBF1, IRDye R© 800cw Conjugated Affinity
Purified Anti Mouse IgG (H&L) (Goat), 926–32210, LI-COR
Biosciences, Licoln, USA] and against rabbit IgG [for pAKT,
926–68071 IRDye R© 680RD Goat anti-Rabbit IgG (H&L), 926–
68071, LI-COR Biosciences] were diluted 1:10,000 in RBB
and blots were incubated for 1.5 h at room temperature.
Detection was done with a LI-COR Odyssey device (LI-COR
Biosciences).
Scharlach Red Staining for Lipids
Cryo liver sections (5 µm; co, n = 4; Igf2, n = 4) were
fixed with 4% normal buffered formalin for 2 min, treated
with 50% ethanol for 3 min, stained for 3min with 0.3%
[m/v] Scharlach Red (0327.1, Roth, Karlsruhe, Germany) in
1:1 aceton/70% ethanol [v/v], rinsed with 70% ethanol and
counterstained with hematoxylin (T865.2, Roth) (Simon et al.,
2014a,b). Slides were embedded in the water based FluoroSafeTM
mounting medium (#345789, Merck, Darmstadt, Germany).
Pictures were captured by an Axio Star plus microscope
coupled to an Axio Cam ICc 1 camera (both Zeiss, Feldbach,
Swiss).
Quantification of Total Lipids
Total lipids were quantified by sulfo-phospho-vanillin
colorimetric method according to published methods
(Cheng et al., 2011). Total lipids were extracted as previously
published (Laggai et al., 2013). Dry lipids were dissolved in
chloroform/methanol (2:1; v/v), loaded into glass vials, from
which the solvent was evaporated at 90◦C. After cooling the
samples down to room temperature samples were incubated with
100 µl sulfuric acid (conc.) at 90◦C for 20min and afterwards
cooled down to room temperature on ice. Fifty microliters of
vanillin-phosphoric acid (0.2mg vanillin per ml 17% ortho-
phosphoric acid) were added, incubated for 10 min, and 100 µl
of the colored solutions were transferred to 96 well plate before
measurement of the absorbance at 550 nm in a SunriseTM Basic
plate reader (Tecan, Maennedorf, Switzerland).
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Quantification of Lipid Classes by Thin
Layer Chromatography (TLC)
Lipid extraction and TLC analysis was performed as recently
described using a sulfuric acid/ethanol mixture for detection
(Laggai et al., 2013). Fifteen milligrams of the freeze-dried
tissue was dispersed with a mixture of hexane/2-propanol [3:2
(v/v)] for 10min, and centrifuged at 4◦C and 10,000 g for
10min. The supernatant was dried under a nitrogen stream,
redissolved in chloroform/methanol [1:1 (v/v)], and applied in
equal amounts onto the TLC plates. After prewashing with a
mixture of chloroform/methanol [2:1 (v/v)] TLC plates were
activated at 110◦C for 1 h. The samples and standard substances
were applied onto the TLC plates, which were developed
in chloroform/methanol/acetic acid/water [50:30:8:3 (v/v/v/v)]
until the liquid phase front reached half of the plate. Then the
development was stopped, the plate was dried, and then fully
developed in heptane/diethyl ether/acetic acid [70:30:2 (v/v/v)].
The ratio area density of each band was quantified using the
ImageJ software as described in Laggai et al. (2013).
Fluorescence Staining for Lipids and
Unesterified Cholesterol
For lipid staining, cryo liver sections (5 µm; co, n = 10; Igf2,
n = 11) were fixed with 4% normal buffered formalin for 5 min,
washed three times for 10 min with PBS, incubated with the
highly selective fluorescent lipid dye LD540 (Astanina et al.,
2015) (0.5 µg/ml in PBS) for 15 min at room temperature,
washed three times with PBS for 10 min, incubated for 1
min with diaminophenylindol HCl (DAPI) (D9542, Sigma
Aldrich) at a concentration of 1 µg/ml, and afterwards washed
three times with PBS. For the staining of free cholesterol,
we performed filipin (F4767-1 mg, Sigma Aldrich) staining
according to published methods (Ioannou et al., 2013; Simon
et al., 2014b). All steps were performed under exclusion
of direct light. Slides were embedded in the water based
FluoroSafeTM mounting medium and visualized with an inverse
fluorescence microscope at 558/583 (excitation/emission)
for LD540 and at 359/461 (excitation/emission) for
DAPI and filipin (Axio Observer, Zeiss, Feldbach, Swiss).
Five randomly selected pictures from each sample were
collected.
Determination of Lipid Droplet Properties
Lipid droplet (LD) number, size, and area were estimated from
LD540 and DAPI stained slides as described above. The five
randomly selected pictures from each sample were analyzed
using the “analyse particles” function of ImageJ 1.47i (Schneider
et al., 2012) as described in published methods (Beller et al.,
2008; Sjøbakk et al., 2013). The lipid droplets and nuclei were
segmented using a manual threshold. Watershed processing was
performed to separate LDs and nuclei. Measurements on the
edges were excluded and lipid droplets were measured in a
pixel size from one to infinity and nuclei were measured in
a pixel size from fifty to infinity and both with parameters
for circularity from zero to one. The total number of particles
and the respective area were measured. The results were
validated by the use of the ImageJ plugin Lipid Droplet Counter
(Author: Samuel Moll; http://imagejdocu.tudor.lu/doku.php?id=
plugin:analysis:droplet_counter:start) as previously published
(Mahammad and Parmryd, 2008; Astanina et al., 2015). The LD
number and the total area were normalized on the nuclei number
from each picture and the mean of the five pictures per slide was
estimated. Average lipid droplet size was estimated as the mean
area of all single lipid droplets per picture and the five pictures
per slide.
Cholesterol and Fatty Acid Measurement
by Gas Chromatography-Mass
Spectrometry (GC-MS)
Cholesterol and fatty acids were measured by GC-MS as reported
recently (Simon et al., 2014b).
Statistical Analysis
Data analysis and statistics were performed with the Origin
8.6 software (OriginLab Corporation, Northampton, USA).
Results are expressed as mean ± SEM. The statistical
significance for normally distributed data was determined
by independent two-sample t-test, for non-normally
distributed data non-parametric Wilcoxon rank sum test
was employed. p < 0.05 were considered as statistically
significant.
RESULTS
Validation of the Igf2 Hydrodynamic Gene
Delivery and Characterization of the Igf2
Model
Hydrodynamic gene delivery has been widely used for the
overexpression of plasmid DNA and the desired product in
murine livers (Zhu et al., 2006; Magnusson et al., 2011; Pinheiro
et al., 2013; Timmermans et al., 2015). Concordantly, total Igf2
mRNA was highly expressed by the injection of the Igf2 plasmid
(Figure 2A). Exogenously delivered Igf2 had no influence on
the endogenic Igf2 mRNA levels (Figure 2B). As a marker for
IGF2-induced insulin signaling the downstream anti-apoptotic
effector of IGF2, AKT (Hamamura et al., 2008; Tybl et al., 2011),
was phosphorylated and therefore activated (Figure 2C). The
liver weight of the Igf2 injected animals was not altered after
7 days (Figure 2D), nor were the serum parameters glucose,
HDL, and triglycerides (Figure 2E). Interestingly, though, serum
cholesterol was increased (Kobayashi et al., 2004). Hydrodynamic
gene delivery usually increases ALT and AST levels, which return
to normal after 3 days. In the Igf2 injected animals ALT was
decreased, and also AST showed a strong tendency of lower levels
compared to animals obtaining the Luc control plasmid. Reduced
liver damage is most likely linked to cytoprotective actions of
IGF2 (Nielsen, 1992; O’Dell and Day, 1998). The AST/ALT ratio
remained unaffected in the Igf2 injected animals compared to the
controls (p = 0.57, co, n = 10; Igf2, n = 11, Wilcoxon rank sum
test).
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FIGURE 2 | Characterization of the IGF2 overexpression model. (A) Exogenous Igf2 mRNA after hydrodynamic gene delivery of the Igf2 plasmid (Igf2) compared
to the control plasmid (co), real-time RT-PCR (co, n = 10; Igf2, n = 11, Wilcoxon rank sum test). Data were normalized to 18S mRNA. (B) Endogenous Igf2 mRNA
levels, real-time RT-PCR (co, n = 10; Igf2, n = 11, independent two-sample t-test), were normalized to 18S mRNA and co. (C) Western blot analysis of
phosphorylated and total AKT protein levels (co, n = 8; Igf2, n = 9, independent two-sample t-test), densitometric data were normalized to α-tubulin and co. (D) Liver
weight on day 7 after plasmid injection (co, n = 10; Igf2, n = 11, independent two-sample t-test). (E) Serum parameters 2 days (glucose) or 7 days (other parameters)
after plasmid injection. Glucose and triglycerides (co, n = 10; Igf2, n = 11, independent two-sample t-test). Cholesterol, HDL, AST, and ALT (co, n = 10; Igf2, n = 11,
Wilcoxon rank sum test). All results are presented as mean ± SEM.
Igf2 Induces Steatotic Histology and Lipid
Accumulation
Scharlach Red staining (Figure 3A) showed that IGF2 induced
features of mild steatosis without any specific zonation of
lipid accumulation. The colorimetric quantification of total
lipids confirmed significantly increased hepatic lipid content
(Figure 3B). Interestingly, signs of liver inflammation, as
validated by the widely used macrophage specific marker
(Khazen et al., 2005; Laggai et al., 2014). EGF-like module-
containing mucin-like hormone receptor-like 1 (Emr1/F4/80)
mRNA levels, were absent in the livers of Igf2 injected
animals (Figure 3C). Since also human steatosis is characterized
not only by quantitative, but also by qualitative changes
in lipid and fatty acid composition (Puri et al., 2007,
2009), we employed TLC and GC-MS methods in order
to decipher the respective composition. Interestingly, the
most distinct increases were found for cholesterol and the
phospholipids phosphatidylethanolamine, phosphatidylserine,
and phosphatidylcholine (Figure 3D). Neither triglyceride nor
ceramide levels were significantly different (Figure 3D). GC-MS
analyses confirmed the increase in liver cholesterol (p= 0.03, co,
n = 10; Igf2, n = 11, Wilcoxon rank sum test). Measurement of
single fatty acids revealed a slight increase of docosahexanoic acid
in Igf2mice (7.75± 0.09 compared to 6.99± 0.18µg/mg tissue in
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FIGURE 3 | IGF2 induces lipid accumulation without inflammation. (A) Representative Scharlach Red staining for lipids (red staining) in animals injected with
Igf2 plasmid (Igf2) compared to the control plasmid (co), nuclei were counterstained with hematoxylin. Original magnification was 200× or 400× (each group, n = 4).
(B) Quantification of total lipids via sulfo-phospho-vanillin colorimetric assay. Igf2 animals normalized to co animals (co, n = 10; Igf2, n = 11, independent two-sample
t-test). (C) mRNA levels of the macrophage marker Emr1 (F4/80), real-time RT-PCR (co, n = 10; Igf2, n = 11, independent two-sample t-test). Data were normalized
to 18S mRNA and co. (D) Quantification of lipid classes by TLC: triglycerides (TG), cholesterol (CH), ceramides (CER), phosphatidylethanolamine (PE),
phosphatidylserine (PS), and phosphatidylcholine (PC) in Igf2 animals normalized to co animals (co, n = 10; Igf2, n = 11, independent two-sample t-test). All results
are presented as mean ± SEM.
control animals; p= 0.008). All other fatty acids were not altered
(data not shown).
Igf2 Induces Lipid Droplet Formation and
Free Cholesterol
Since phospholipid levels were elevated and phospholipids are
mainly incorporated into the lipid droplet coat and into cell
membranes, we analyzed lipid droplet size and number. Lipid
droplet staining with LD540 revealed an increased number
of lipid droplets in the livers of Igf2 injected mice, but the
lipid droplet size showed no distinct alteration (Figure 4A).
The livers of Igf2 injected mice also showed a higher amount
of free cholesterol visualized with filipin staining (Figure 4B).
Concordantly, the mRNA level of the key enzyme involved in
cholesterol biosynthesis, hydroxy-methyl-glutaryl-coenzyme A
reductase (Hmgcr) (Lonardo and Loria, 2012), was upregulated
in livers of Igf2 injected animals (Figure 4C).
Igf2 Effects on Transcriptional Regulators
of Lipogenesis
Igf2 injection induced the expression of the lipogenic
transcription factor SREBF1 on mRNA (Figure 5A) and
protein (Figure 5A) level. Accordingly, a number of direct
transcriptional targets of SREBF1 were slightly induced
(Figure 5B). The glucose dependent transcriptional regulator
of lipogenic genes carbohydrate response element binding
protein (Mlxipl) (Postic and Girard, 2008) was not affected
(Figure 5C) by the Igf2-induced activation of the insulin
pathway. Interestingly, the gene expression of the main
transcriptional regulator of MLXIPL and SREBF1 itself,
liver-X-receptor alpha (Nr1h3), was not regulated by Igf2
(Figure 5D). Igf2 injection induced the expression of carnitine
palmitoyltransferase 1A (Cpt1a) mRNA (Figure 5E), which is
responsible for mitochondrial fatty acid oxidation (Reddy and
Rao, 2006), and had rather no effect onmRNA of the peroxisomal
fatty acid oxidation inducing peroxisome proliferator activated
receptor alpha (Ppara) (Reddy, 2001) (Figure 5F).
DISCUSSION
IGF2 has been described to be overexpressed in cirrhosis and
HCC (Iizuka et al., 2002; Sedlaczek et al., 2003; Couvert et al.,
2008; Kessler et al., 2013). Interestingly, despite two studies
describing elevated IGF2 in human steatosis and steatohepatitis
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FIGURE 4 | IGF2 induces lipid droplet formation but has no influence on lipid droplet size. (A) Representative LD540 fluorescence staining for lipid droplets
(LD, yellow droplets) in animals injected with Igf2 plasmid (Igf2) compared to the control plasmid (co), nuclei were stained with DAPI (blue) (scale bar: 20 µm) (upper
panel). Five randomly selected pictures per sample were collected and analyzed with ImageJ. Counted LDs were normalized to the nuclei count (lower panel, left).
Total LD area was normalized to the nuclei count (lower panel, middle). Total LD size was estimated as the mean area of all counted LDs (lower panel, right) (co, n =
10; Igf2, n = 11, independent two-sample t-test). (B) Representative filipin fluorescence staining for free cholesterol (black droplets) in Igf2 and co animals (co, n = 10;
Igf2, n = 11, arrows designate examples for free cholesterol). (C) Levels of Hmgcr mRNA, real-time RT-PCR (co, n = 10; Igf2, n = 11, Wilcoxon rank sum test). Data
were normalized to 18S mRNA and co. All results are presented as mean ± SEM.
(Chiappini et al., 2006) and elevated Igf2 in murine steatosis
(Tybl et al., 2011) and one study showing serum IGF2 inversely
correlating with NAFLD-related fibrosis, functional implications
of IGF2 in steatosis development are completely unknown. In
contrast to IGF2, IGF1 was shown to be downregulated in
steatosis (Völzke et al., 2009; Mallea-Gil et al., 2012). Whether
the observed downregulation of IGF1 in steatotic patients has a
functional role in steatosis development, however, has not been
evaluated sufficiently in the literature. To our knowledge, only
one study showed that IGF1 can antagonize growth hormone
deficiency-induced steatosis (Nishizawa et al., 2012). Up to
now it is not completely clear, what distinguishes the effects
of IGF2 from the ones of IGF1 in steatosis. Still, the two
IGFs show different receptor binding affinities for the IGF
and insulin receptors (reviewed in White, 2003, 2006) and
therefore signaling can be different. Furthermore, the different
expression of both IGFs during development (reviewed in Nakae
et al., 2001) also points to specific actions of IGF1 or IGF2,
respectively.
Our model of transient hepatic overexpression of IGF2
revealed a causal link of IGF2 overexpression and lipid
accumulation. The lack of any zonation in this model is in
line with findings in a model of Igf2 mRNA binding protein
2-2 transgenic mice (Tybl et al., 2011), in which the lipid
accumulation is IGF2-dependent (Laggai et al., 2014). When
compared with other vector-mediated gene delivery systems,
such as viral systems, transient overexpression by hydrodynamic
gene delivery has the advantage of being a simplemethod without
the requirement of long and laborious preparation of virus or any
special gene transfer device. Furthermore, complications known
from adenoviral vectors, such as host immune responses and loss
of transfected cells, can be avoided (Zhu et al., 2006).
Interestingly, especially phospholipids were increased in
IGF2 overexpressing livers. The LD membrane consists of a
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FIGURE 5 | Igf2 induces lipogenesis. (A) Lipogenic transcription factor
Srebf1c mRNA (left) and SREBF1 protein (right) compared to the control
plasmid (co). Left: real-time RT-PCR data (co, n = 10; Igf2, n = 11,
independent two-sample t-test) were normalized to 18S mRNA and co. Right:
Western blot analysis of SREBF1 (co, n = 8; Igf2, n = 9, independent
two-sample t-test), densitometric data were normalized to α-tubulin and co.
(B) Expression of SREBF1 target genes Fasn, Elovl6, Acaca, Scd, Gck
determined by real-time RT-PCR (co, n = 10; Igf2, n = 11), normalized to 18S
mRNA. Data are shown as fold of co. (c-f) Mlxipl (C), Nr1h3 (D), Cpt1 (E),
Ppara (F) mRNA expression, determined by real-time RT-PCR data (co,
n = 10; Igf2, n = 11, independent two-sample t-test), normalized to 18S
mRNA and co. All results are presented as mean ± SEM.
phospholipid monolayer, in which phosphatidylcholine is the
most prominent phospholipid (Leber et al., 1994). The number of
LDs of various sizes has been reported to be increased in murine
steatosis (Kochan et al., 2013). Acute steatosis is characterized by
rather small LDs, which maturate in chronic steatosis (Pawella
et al., 2014).
Also serum levels of phospholipids have been demonstrated
to be elevated in NASH patients (Anjani et al., 2015), but
were also reported to be decreased during NAFLD progression
(Puri et al., 2007), and discussed to have hepato-protective
effects (Chamulitrat et al., 2009). Beside the cytoprotective
effect of IGF2 the increased phospholipids might be a reason
for the lack of an increase in transaminases, since NAFLD
is usually accompanied by an increase in transaminases,
especially ALT. However, significant liver disease can exist with
transaminase levels in the normal range (Papandreou et al.,
2007).
LDs were reported to contain high levels of free cholesterol
in adipocytes (Prattes et al., 2000). In line with this finding
IGF2 overexpressing livers showed increased free cholesterol
levels. Steatosis is defined by an accumulation of fat in
the liver, mostly in the form of triglycerides (Cohen et al.,
2011), but also several other lipid classes, e.g., cholesterol and
phospholipids, are stored (Alkhouri et al., 2009). Interestingly,
accumulation of triglycerides is not needed for the development
of NASH per se and might have a rather protective effect
(McClain et al., 2007; Yilmaz, 2012). The accumulation of
free cholesterol was suggested to play a critical role in NASH
development (Tomita et al., 2014) and was shown to positively
correlate with the severity of NASH (Caballero et al., 2009;
Van Rooyen et al., 2011; Min et al., 2012; Ioannou et al.,
2013; Simon et al., 2014b; Tomita et al., 2014). Diet-induced
hepatic cholesterol uptake was shown to specifically increase
hepatic cholesterol, but not triglycerides (Marí et al., 2006).
The latter study underlines that free cholesterol accumulation,
but not triglycerides or free fatty acid storage, plays a key
role in sensitizing the liver to the development of hepatic
inflammation.
Since both the key enzyme in cholesterol biosynthesis, HMG-
CoAR, and blood cholesterol levels were elevated in IGF2
overexpressing animals, we suggest that cholesterol accumulation
in these animals is due to increased de novo synthesis of
cholesterol. HMG-CoAR is usually induced by SREBF2, but can
also be upregulated by SREBF1 (Horton et al., 1998). De novo
lipid synthesis is regulated in a complex interplay induced by
a set of lipogenic transcription factors, such as liver X receptor
alpha (LXR-α/NR1H3), sterol regulatory element binding
transcription factor 1 (SREBF1/SREBP1), and carbohydrate
responsive element binding protein (ChREBP/MLXIPL) (Musso
et al., 2009). IGF2 as well as IGF1 and insulin treatment
have been shown to induce SREBF1 via activation of the
insulin and IGF1 receptor (Smith et al., 2008; Laggai et al.,
2014). SREBF1 target genes, which are also involved in de
novo lipid synthesis and steatosis development (Postic and
Girard, 2008), were slightly upregulated in IGF2 overexpressing
mice supporting lipogenic actions of IGF2. One of the
most relevant inducers of lipid degradation in the liver is
PPARa (Lefebvre et al., 2006), which was downregulated in
IGF2 overexpressing mice. Upregulation of lipolytic Cpt1a,
as also observed in IGF2 overexpressing livers, has been
described as a compensatory mechanism, which is not able
to prevent steatosis (Monetti et al., 2007; Monsénégo et al.,
2012).
Taken together, our data show that hepatic IGF2
overexpression can lead to an increased lipid droplet formation
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and free cholesterol accumulation and might therefore play a
causal role in steatosis initiation.
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